company background image
PBYI

Puma Biotechnology NasdaqGS:PBYI Stock Report

Last Price

US$3.27

Market Cap

US$149.0m

7D

-10.4%

1Y

-54.7%

Updated

16 Aug, 2022

Data

Company Financials +
PBYI fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health2/6
Dividends0/6

PBYI Stock Overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.

Puma Biotechnology, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Puma Biotechnology
Historical stock prices
Current Share PriceUS$3.27
52 Week HighUS$7.84
52 Week LowUS$1.60
Beta0.66
1 Month Change3.81%
3 Month Change68.56%
1 Year Change-54.71%
3 Year Change-69.67%
5 Year Change-96.01%
Change since IPO-75.78%

Recent News & Updates

Aug 04

Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M

Puma Biotechnology press release (NASDAQ:PBYI): Q2 Non-GAAP EPS of $0.28. Revenue of $59.5M (+11.4% Y/Y). At June 30, 2022, Puma had cash, cash equivalents and marketable securities of $60.8M, compared to cash, cash equivalents and marketable securities of $82.1M at December 31, 2021.

Shareholder Returns

PBYIUS BiotechsUS Market
7D-10.4%1.4%3.6%
1Y-54.7%-19.6%-9.6%

Return vs Industry: PBYI underperformed the US Biotechs industry which returned -19.6% over the past year.

Return vs Market: PBYI underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is PBYI's price volatile compared to industry and market?
PBYI volatility
PBYI Average Weekly Movement12.2%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: PBYI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: PBYI's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2010196Alan Auerbachhttps://www.pumabiotechnology.com

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company’s drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd.

Puma Biotechnology, Inc. Fundamentals Summary

How do Puma Biotechnology's earnings and revenue compare to its market cap?
PBYI fundamental statistics
Market CapUS$148.97m
Earnings (TTM)-US$34.48m
Revenue (TTM)US$206.86m

0.7x

P/S Ratio

-4.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PBYI income statement (TTM)
RevenueUS$206.86m
Cost of RevenueUS$47.94m
Gross ProfitUS$158.92m
Other ExpensesUS$193.40m
Earnings-US$34.48m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.76
Gross Margin76.83%
Net Profit Margin-16.67%
Debt/Equity Ratio494.9%

How did PBYI perform over the long term?

See historical performance and comparison